Original results from the phase 3 OLYMPIA 1 (NCT04501679) and 2 (NCT04501666) trials demonstrated the safety and efficacy of nemolizumab administered subcutaneously every 4 weeks in 560 patients ...

Home NICE Guidance Conditions and diseases Infections Skin infections Nemolizumab for treating prurigo nodularis [ID6451] In development [GID-TA11566] Expected publication date: TBC Project ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

We diagnosed this patient as having Chondrodermatitis Nodularis Chronica Helicis (CNCH) and started treatment with protective padding placed around the external ear and topical 0.5% halometasone cream ...

Amber Specialty Pharmacy Announces Access to Galderma's New Medication for Prurigo Nodularis September 12, 2024 12:01 PM Eastern Daylight Time ...

The Food and Drug Administration (FDA) has approved Nemluvio ® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis. Interleukin (IL)-31 is a neuroimmune cytokine that is ...

The FDA on Tuesday signed off on Galderma’s IL-31 blocker nemolizumab for the treatment of adults with the chronic skin disorder prurigo nodularis. The subcutaneous injection will be marketed under ...

Last accessed April 2024 Kwatra SG, et al. Phase III trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89. doi: 10.1056/NEJMoa2301333 ...